Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of MBS2320 plus methotrexate in rheumatoid arthritis with inadequate response to methotrexate
2020-005496-13Phase 2Completed
- Sponsor
- Modern Biosciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Leramistat in rheumatoid arthritis (RA) (4 arms), sponsored by Modern Biosciences. Primary endpoint: Composite clinical response at Week 12. Started Apr 2022; status: completed.
02
Drugs
Leramistat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-005496-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005496-13.